

# CITATION REPORT

List of articles citing

## Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial

DOI: 10.7326/m20-6519

Annals of Internal Medicine, 2021, 174, 344-352.

**Source:** <https://exaly.com/paper-pdf/77925530/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
63	Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e844-e847	11.6	2
62	COVID-19 illness and autoimmune diseases: recent insights. <i>Inflammation Research</i> , <b>2021</b> , 70, 407-428	7.2	5
61	Correction: Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 435	8	2
60	Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009406	7.6	7
59	A living WHO guideline on drugs to prevent covid-19. <i>BMJ, The</i> , <b>2021</b> , 372, n526	5.9	31
58	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1257-1266	4	4
57	Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. <i>Trials</i> , <b>2021</b> , 22, 224	2.8	4
56	Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? - Authors' reply. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e172-e173	14.2	1
55	Prophylaxis for COVID-19: a systematic review. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 532-537	9.5	12
54	Prophylaxis against covid-19: living systematic review and network meta-analysis. <i>BMJ, The</i> , <b>2021</b> , 373, n949	5.9	31
53	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1254-1268	4.5	42
52	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. <i>Food and Chemical Toxicology</i> , <b>2021</b> , 151, 112106	4.7	3
51	Impact of Prophylactic Hydroxychloroquine on People at High Risk of COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
50	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19. Systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.		
49	Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 108, 370-376	10.5	3
48	Test it earlier, result it faster, makes us stronger: how rapid viral diagnostics enable therapeutic success. <i>Current Opinion in Virology</i> , <b>2021</b> , 49, 111-116	7.5	1
47	Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection.		

46	Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19. <i>American Journal of Medicine</i> , <b>2021</b> ,	2.4	3
45	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials. <i>The Lancet Regional Health Americas</i> , <b>2021</b> , 2, 100062		9
44	Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2021</b> , 22, 661	2.8	3
43	Health impact and cost of COVID-19 prophylaxis with monoclonal antibodies.		2
42	Low dose hydroxychloroquine prophylaxis for COVID-19 in a prospective study.		
41	The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic. <i>Trials</i> , <b>2021</b> , 22, 603	2.8	1
40	Nanoparticles of ZnO/Berberine complex contract COVID-19 and respiratory co-bacterial infection in addition to elimination of hydroxychloroquine toxicity. <i>Journal of Pharmaceutical Investigation</i> , <b>2021</b> , 51, 1-23	6.3	3
39	Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 6277-6286	2.3	14
38	derived carbon dots as a potential theranostic agent to combat the COVID-19 crisis. <i>Sensors International</i> , <b>2021</b> , 2, 100102	6.1	13
37	Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data.		2
36	ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
35	Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. <i>Systematic Reviews</i> , <b>2021</b> , 10, 294	3	0
34	Risk of SARS-CoV-2 acquisition is associated with individual exposure but not community-level transmission.. <i>Journal of Infectious Diseases</i> , <b>2022</b> ,	7	1
33	Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2142796	10.4	2
32	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis.. <b>2022</b> ,		1
31	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients in a Systematic Review.		0
30	Self-Assessed Severity as a Determinant of COVID-19 Symptom Specificity: A Longitudinal Cohort Study.. <i>Clinical Infectious Diseases</i> , <b>2022</b> ,	11.6	
29	Detection and kinetics of subgenomic SARS-CoV-2 RNA viral load in longitudinal diagnostic RNA positive samples.. <i>Journal of Infectious Diseases</i> , <b>2022</b> ,	7	0

28	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.. <i>MBio</i> , <b>2021</b> , 12, e0334721	7.8	7
27	Hydroxychloroquine pre-exposure prophylaxis for COVID-19 among healthcare workers: Initial experience from India.. <i>Journal of Family Medicine and Primary Care</i> , <b>2022</b> , 11, 1140-1145	1.5	
26	Rationale and Design of the COVID-19 Outpatient Prevention Evaluation (COPE - Coalition V) Randomized Clinical Trial: Hydroxychloroquine vs. Placebo in Non-Hospitalized Patients.. <i>Arquivos Brasileiros De Cardiologia</i> , <b>2022</b> , 118, 378-387	1.2	1
25	Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2148325	10.4	2
24	Maoto, a traditional herbal medicine, for post-exposure prophylaxis for Japanese healthcare workers exposed to COVID-19: A single center study.. <i>Journal of Infection and Chemotherapy</i> , <b>2022</b> ,	2.2	1
23	The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e222973	10.4	3
22	Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial.. <i>The Lancet Regional Health Americas</i> , <b>2022</b> , 11, 100243		0
21	Implementation of a fully remote randomized clinical trial with cardiac monitoring. <i>Communications Medicine</i> , <b>2021</b> , 1,		0
20	Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 1218	4	0
19	Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study. <i>Expert Review of Anti-Infective Therapy</i> , <b>2021</b> ,	5.5	
18	Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19.		
17	A Review of the Ring Trial Design for Evaluating Ring Interventions for Infectious Diseases.. <i>Epidemiologic Reviews</i> , <b>2022</b> ,	4.1	
16	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , <b>2022</b> , 15, 634	5.2	1
15	Hydroxychloroquine plus personal protective equipment versus personal protective equipment alone for the prevention of laboratory-confirmed COVID-19 infections among healthcare workers: a multicentre, parallel-group randomised controlled trial from India. <i>BMJ Open</i> , <b>2022</b> , 12, e059540	3	1
14	Dimethoxycurcumin Acidifies Endolysosomes and Inhibits SARS-CoV-2 Entry. <i>Frontiers in Virology</i> , 2,		0
13	Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19.		
12	ZnO-chlorogenic acid nanostructured complex inhibits Covid-19 pathogenesis and increases hydroxychloroquine efficacy. <b>2022</b> , 34, 102296		1
11	Evolution of Approaches to Therapeutic Prevention and Treatment of the New Coronavirus Infection. <b>2022</b> , 92, 430-436		0

- 10 Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: a retrospective, propensity-matched cohort study. **2022**, ○
- 9 Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. **2022**, 12, 1456 ○
- 8 Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. **2022**, 17, e0273526 ○
- 7 Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 6
- 6 Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer. **2022**, 14, 2551 ○
- 5 The Myth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19 is far from reality. **2023**, 13, ○
- 4 A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. **2023**, 11, ○
- 3 A Simultaneous Extraction/Derivatization Strategy for Quantitation of Vitamin D in Dried Blood Spots Using LCMS/MS: Application to Biomarker Study in Subjects Tested for SARS-CoV-2. **2023**, 24, 5489 ○
- 2 Inclusion in clinical research: cross-sectional study assessing potential barriers to informed consent in randomized controlled trials published in top general and internal medical journals. ○
- 1 Factors Related to Severity, Hospitalization, and Mortality of COVID-19 Infection among Patients with Autoimmune Diseases. **2023**, 8, 227 ○